Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (LRMR): 2 pipeline candidates · ~14 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.5 months
D/E 0.32 · 0% dilution
Lead: Phase 2
2 candidates
N/A
7 buys · 0 sells (180d)
A transparent, data-derived signal for Larimar Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$355.8M
Cash
$177.9M
Quarterly Burn
$44.6M
Runway
13.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| cti-1601 | Phase 2 |
| nomlabofusp | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
160
Total value held
$371.0M
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 35,606,974 | $160.2M |
| vanguard capital management llc | 5,732,698 | $25.8M |
| blackrock, inc. | 3,752,200 | $16.9M |
| millennium management llc | 3,625,278 | $16.3M |
| driehaus capital management llc | 2,934,399 | $13.2M |
| woodline partners lp | 2,801,700 | $12.6M |
| dafna capital management llc | 2,029,164 | $9.1M |
| goldman sachs group inc | 1,651,585 | $7.4M |
| deep track capital, lp | 1,500,000 | $6.8M |
| rtw investments, lp | 1,500,000 | $6.8M |
Showing top 10 of 160 institutional holders of Larimar Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Larimar Therapeutics, Inc.'s pipeline?
Larimar Therapeutics, Inc. (LRMR) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Larimar Therapeutics, Inc.'s lead drug candidate?
Larimar Therapeutics, Inc.'s most advanced tracked candidate is cti-1601 (Phase 2) for Friedreich Ataxia.
What is Larimar Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Larimar Therapeutics, Inc. has approximately 13.5 months of cash runway.
What is Larimar Therapeutics, Inc.'s market capitalization?
Larimar Therapeutics, Inc.'s market capitalization is approximately $355.8M.
Who is the CEO of Larimar Therapeutics, Inc.?
Dr. Carole S. Ben-Maimon M.D. is the chief executive officer of Larimar Therapeutics, Inc. (LRMR).
Get the full picture on Larimar Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.